• Home
  • Terms of Use
  • Privacy Policy
  • Disclosure
Sunday, May 22, 2022
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Videos
No Result
View All Result
Omicron b11529 Variant
No Result
View All Result
Home Covid-19

Homegrown MRNA Thai Vaccine For Covid-19 Could Be Ready By Year End — Report – Endpoints News

by NewsReporter
May 10, 2022
in Covid-19
Reading Time: 8 mins read
Share on FacebookShare on Twitter

Thai Public Health Minister Anutin Charnvirakul (Photo by Vachira Vachira/NurPhoto via AP)

Home­grown mR­NA Thai vac­cine for Covid-19 could be ready by year end — re­port

Josh Sullivan

Associate Editor

The Thai Food and Drug Ad­min­is­tra­tion will soon re­view tri­al re­sults from its coun­try’s first lo­cal­ly-de­vel­oped Covid-19 vac­cine, which us­es the same mR­NA tech­nol­o­gy that suc­cess­ful vac­cines from Pfiz­er/BioN­Tech and Mod­er­na have al­so em­ployed. If all goes well, Thai­land will roll out its first home­grown vac­cine by the end of this year, its gov­ern­ment has said.

The first lot of the vac­cine was pro­duced by BioNet-Asia, and de­vel­oped by Chu­la­longko­rn Uni­ver­si­ty re­searchers, the Bangkok Post re­port­ed. The jab, dubbed Chu­la­Cov19, has yet to be­gin clin­i­cal tri­als in hu­mans but ex­pects to lat­er this year, the Chu­la Vac­cine Re­search Cen­ter said. The cen­ter worked in col­lab­o­ra­tion with UPenn Pro­fes­sor Drew Weiss­man, who al­so worked on the mR­NA vac­cine tech that Pfiz­er/BioN­Tech de­ployed.

The vac­cine’s pro­duc­tion was spurred by a 2.31 bil­lion baht ($67 mil­lion) in­vest­ment from the gov­ern­ment last year.

BioNet-Asia can make 20 mil­lion dos­es a year. More than a dozen vac­cines are be­ing de­vel­oped, ac­cord­ing to Bloomberg, in an ef­fort to cut back re­liance on for­eign sup­ply. Chu­la­longko­rn’s is the most ad­vanced. Thai­land is al­so home to As­traZeneca’s on­ly man­u­fac­tur­ing site in south­east Asia.

Racha­da Dhnadi­rek

Deputy gov­ern­ment spokes­woman Racha­da Dhnadi­rek told the Bangkok Post that Thai­land’s goal of pro­duc­ing its own vac­cine aligns with its 10-year strate­gic plan to be­come a med­ical hub by 2026.

“The goal was set be­fore the Covid-19 pan­dem­ic be­gan, and by be­com­ing a vac­cine pro­duc­tion cen­ter, more Thai peo­ple will have ac­cess to the vac­cine,” she told the out­let.

Last Ju­ly, As­traZeneca ran in­to vac­cine dis­tri­b­u­tion is­sues in Thai­land and was forced to ask the gov­ern­ment for a five-month ex­ten­sion of the time­line to de­liv­er 61 mil­lion dos­es, bring­ing its dead­line all the way to this May. The hic­cup led Thai­land to re­port­ed­ly con­sid­er im­pos­ing ex­port bans on lo­cal­ly pro­duced dos­es of the jab, as waves of the virus hit its pop­u­la­tion hard.

Two weeks ago, the Quad Vac­cine Part­ner­ship hand­ed over a con­sign­ment of Cov­di-19 vac­cines from In­dia to the gov­ern­ment of Thai­land. More than 200,000 made-in-In­dia dos­es of Cov­o­vax were giv­en to the Min­is­ter of Pub­lic Health Anutin Charn­vi­rakul on April 21 in Bangkok.

SPONSORED

May 9, 2022 06:00 AM EDT

Biotech in­vestors: how to find val­ue in a bear mar­ket

Chris McCarthy

Healthcare Desk Sector Strategist, RBC Capital Markets

How are top investors navigating the longest biotech bear market in almost 20 years? RBC Capital Markets Healthcare Desk Sector Strategist Chris McCarthy discusses key fundamentals, macro-awareness and the continued impact of COVID with HealthCor’s Ben Snedeker and Omega Funds founder Otello Stampacchia.

Picking biotech winners

Biotech indexes may be down, but both Snedeker and Otello Stampacchia, Ph.D., Founder and Managing Director of Omega Funds, see opportunities in the market. In Snedeker’s opinion, investors need to seek out companies with the potential for meaningful revenue growth, particularly those that are mispriced in the current bear market.

Vijay Pande (L) and Jorge Conde

May 9, 2022 09:47 AM EDTUpdated 4 hours ago

Is this Sil­i­con Val­ley duo the fu­ture of biotech?

SAN FRANCISCO — Seven years ago, Silicon Valley’s brashest venture capitalist invited a soft-spoken Stanford biophysicist out for pancakes not far from here, planning to make a request he publicly swore he’d never make.

By that point, Marc Andreessen had already completed his rise from tech prince — Time magazine literally put him on the cover on a throne in 1996 — to tech kingmaker. The baby-faced founder of Netscape, briefly the world’s dominant web browser, re-emerged in 2009 as head of Andreessen Horowitz, or a16z for short, that quickly became one of the industry’s most sought-after VC firms.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Damien McDevitt, Aspen Neuroscience CEO

May 9, 2022 09:00 AM EDTUpdated 10:29 AM

Ex­clu­sive: As­pen Neu­ro­science col­lects large Se­ries B to com­pete against Bay­er’s Parkin­son’s cell ther­a­py

Kyle LaHucik

Associate Editor

Damien McDevitt thinks frequently about the name Aspen Neuroscience. Specifically, should the neuroscience portion be dropped as the San Diego biotech considers expanding beyond the CNS?

McDevitt, the 21-year GlaxoSmithKline veteran and former Akcea Therapeutics CEO who took over the helm of Aspen in January 2021, now has even more deep-pocketed investors to help him and his 60-plus employee team consider their voyage beyond Parkinson’s thanks to a $147.5 million Series B.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 141,500+ biopharma pros reading Endpoints daily — and it’s free.

CEO Clay Siegall (L) and CMO Roger Dansey, Seagen

May 9, 2022 07:05 AM EDTUpdated 07:20 AM

In wake of do­mes­tic vi­o­lence al­le­ga­tion, long­time Seagen CEO Clay Sie­gall goes on leave

Clay Siegall, the co-founder and longtime CEO of Seagen, is on a leave of absence following an alleged incident of domestic violence, the company revealed Monday morning.

While Siegall — who informed the company that he’s in the middle of a divorce — denied those allegations, the Seagen board of directors formed a committee to conduct an investigation, with the help of a law firm.

In the meantime, Roger Dansey, CMO since 2018, will step in as interim CEO to lead the company as it navigates the expansion of its commercial antibody-drug conjugates while plotting the clinical advancements of experimental ones.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 141,500+ biopharma pros reading Endpoints daily — and it’s free.

Michael Kloss, eureKING CEO

May 9, 2022 10:16 AM EDTUpdated 10:39 AM

Ex-Sanofi CEO on board, a new $158M SPAC de­buts look­ing to shake up the Eu­ro­pean CD­MO mar­ket

Josh Sullivan

Associate Editor

What do you get when some of the most powerful CDMOs in the world join forces? The first SPAC dedicated to meeting the critical demand for biomanufacturing on the continent.

eureKING will be a publicly listed shell company. It is backed by eureKARE, the investment company focused on developing synthetic biology and microbiome innovation across Europe.

The company has plans to raise 150 million euros, Reuters reported. It will list on the Euronext Paris, and has identified 40 manufacturing targets. Michael Kloss, formerly of PHC Holdings, told Reuters that it plans to swallow three CDMOs that each make roughly 50 million euros a year over the next few years.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 141,500+ biopharma pros reading Endpoints daily — and it’s free.

Try­ing to avoid a CRL? New FDA draft guid­ance talks ben­e­fit-risks on qual­i­ty as­sess­ments

Zachary Brennan

Senior Editor

As manufacturing-related issues continue to plague the biopharma industry and lead to dozens or more FDA rejections, or CRLs, each year, the agency on Monday released new draft guidance spelling out how it assesses quality risks, sources of uncertainty, and possible mitigation strategies.

The FDA’s product quality assessment, according to the 12-page draft, determines whether an applicant’s product development studies, manufacturing process, and control strategy will consistently result in a finished drug or biologic of acceptable quality when manufactured at the facilities named in the application.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 141,500+ biopharma pros reading Endpoints daily — and it’s free.

Il­lu­mi­na forced to pay al­most $334M as it los­es DNA se­quenc­ing patent case

Tyler Patchen

News Reporter

A federal jury in Delaware on Friday ordered Illumina to pay Complete Genomics Inc., a subsidiary of the BGI Group, the world’s largest maker of commercial genetic sequencers, almost $334 million, finding Illumina infringed on two DNA sequencing patents.

The case, began in 2019 when CGI sued the San Diego-based biotech over the patents, alleging that Illumina’s “two-channel” sequencing system and its kits that prepare DNA fragments for sequencing violated CGI’s patent rights.

Timo Lappalainen, Orion CEO

Sweep­ing re­org at Ori­on — cen­tered around can­cer and pain — claims 30 staffers

More than a month after Orion signaled that it’s going to bring out the budget axe in search of a major shift, the Bayer partner has settled on a plan — and finalized how deep the cuts are going to be.

The Finnish biotech has decided to focus on cancer and pain moving forward while moving out of neurodegenerative and rare diseases. In addition, it’s dropping the development of a chronic obstructive pulmonary disease treatment.

Clay Siegall, Seagen CEO (Dimitrios Kambouris/Getty Images for Gabrielle’s Angel Foundation)

May 9, 2022 03:17 PM EDTUpdated 03:35 PM

Seagen CEO Clay Sie­gall was placed on leave af­ter an April 23 ar­rest for do­mes­tic vi­o­lence gross mis­de­meanor

Kyle LaHucik

Associate Editor

Clay Siegall was placed on leave from his posts as CEO and chairman of prominent Seattle-area biotech Seagen after an arrest by the Edmonds Police Department on April 23.

At 3:41 a.m. local time on April 23, police were dispatched to Siegall’s home, where he was arrested on charge of 4th degree assault domestic violence gross misdemeanor, the police department’s public information officer confirmed to Endpoints News. Siegall had a court appearance the next day, the officer said, noting the investigation is now in the court’s hands.

Related Posts

x-con-returns-to-myrtle-beach-after-covid-19-cancellations-–-wmbf

X-Con Returns To Myrtle Beach After COVID-19 Cancellations – WMBF

by NewsReporter
May 22, 2022
0

MYRTLE BEACH, S.C. (WMBF) - Myrtle Beach’s annual comic book convention, X-Con World, is back after being canceled the past two years due to COVID-19.The annual event featured special guests, comics, toys, costumes and art. Several businesses from the Grand Strand and beyond also took advantage of the opportunity to...

here’s-what-experts-say-1918-flu-pandemic-can-teach-about-covid-|-kgwcom-–-kgw.com

Here’s What Experts Say 1918 Flu Pandemic Can Teach About COVID | Kgw.com – KGW.com

by NewsReporter
May 22, 2022
0

A team of health and history experts recently published an article that compares the 1918 flu pandemic to the current COVID pandemic. CORVALLIS, Ore. — The COVID-19 pandemic has changed lives across the world since it started over two years ago. Now, U.S. health officials are suggesting a big coronavirus surge...

here’s-where-to-get-the-new-covid-19-anti-viral-medication-in-nj-–-new-jersey-101.5-fm

Here’s Where To Get The New COVID-19 Anti-Viral Medication In NJ – New Jersey 101.5 FM

by NewsReporter
May 22, 2022
0

We’ve come a long way when it comes to COVID-19 treatments.At the very beginning of the pandemic, way back when, the only thing you could do when you were diagnosed with COVID-19 was to stay at home and just pray that yours didn’t turn into a case that was scary...

palm-beach-county-moves-into-high-covid-19-transmission-category-after-cdc-confirms-‘processing-error’-–-wptv-news-channel-5-west-palm

Palm Beach County Moves Into High COVID-19 Transmission Category After CDC Confirms ‘processing Error’ – WPTV News Channel 5 West Palm

by NewsReporter
May 22, 2022
0

Three South Forida Counties — Palm Beach, Broward and Miami-Dade — have moved into the highest of three COVID-19 community transmission levels after a "data processing error” was noted the Centers for Disease Control and Prevention.Three categories as determined by the CDC are high, medium and low — with different...

experts-say-texas-is-ready-for-latest-covid-19-uptick-but-advise-caution-–-kvue.com

Experts Say Texas Is Ready For Latest COVID-19 Uptick But Advise Caution – KVUE.com

by NewsReporter
May 22, 2022
0

It’s still unclear what the increase in cases will mean for the state, but doctors and hospitals say Texas is better prepared to face a surge than before. (The Texas Tribune) Texas and the rest of the U.S. are experiencing a slight uptick in COVID-19 cases — but health experts...

alex-jones’-unfounded-claims-that-monkeypox-outbreak-due-to-covid-19-vaccines-–-forbes

Alex Jones’ Unfounded Claims That Monkeypox Outbreak Due To Covid-19 Vaccines – Forbes

by NewsReporter
May 22, 2022
0

Alex Jones, the founder of Infowars and seller of supplements, is now suggesting that Covid-19 ... vaccines are behind the monkeypox outbreak. (Photo by Jon Cherry/Getty Images) Getty Images Well, it was only a matter of time before someone started blaming the Covid-19 vaccines for the monkeypox outbreak. After all,...

Omicron b11529 Variant

© 2021

Navigate Site

  • Home
  • Terms of Use
  • Privacy Policy
  • Disclosure

Follow Us

No Result
View All Result
  • Home

© 2021